Pan-transcriptome-based candidate therapeutic discovery for idiopathic pulmonary fibrosis

BACKGROUND: There are two US Food and Drug Administration (FDA)-approved drugs, pirfenidone and nintedanib, for treatment of patients with idiopathic pulmonary fibrosis (IPF). However, neither of these drugs provide a cure. In addition, both are associated with several drug-related adverse events. H...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Ther Adv Respir Dis
Autors principals: Wang, Yunguan, Yella, Jaswanth K., Ghandikota, Sudhir, Cherukuri, Tejaswini C., Ediga, Harshavardhana H., Madala, Satish K., Jegga, Anil G.
Format: Artigo
Idioma:Inglês
Publicat: SAGE Publications 2020
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7659024/
https://ncbi.nlm.nih.gov/pubmed/33167785
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1753466620971143
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars